Ziprasidone versus other atypical antipsychotics for schizophrenia

Area of Science:

• Psychiatry and Pharmacology
• Clinical Trials and Evidence-Based Medicine

Background:

• Second-generation (atypical) antipsychotics are first-line treatments for schizophrenia globally.
• Significant debate exists regarding the comparative efficacy and tolerability of various atypical antipsychotics.

Purpose of the Study:

• To evaluate the comparative efficacy and tolerability of ziprasidone against other atypical antipsychotics for schizophrenia.
• To synthesize evidence from randomized controlled trials comparing ziprasidone with other second-generation antipsychotics.

Main Methods:

• Systematic review of randomized, controlled trials comparing oral ziprasidone with amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, or zotepine.
• Searched the Cochrane Schizophrenia Group Specialised Register and contacted pharmaceutical companies for data.
• Extracted and analyzed data using random-effects models, calculating weighted mean differences and relative risks.

Main Results:

• Nine randomized controlled trials (RCTs) involving 3361 participants were included; overall discontinuation rate was high (59.1%).
• Ziprasidone showed lower acceptability than olanzapine and risperidone, and was less efficacious than amisulpride, olanzapine, and risperidone.
• Ziprasidone demonstrated less weight gain and fewer cholesterol increases than olanzapine, quetiapine, and risperidone, but more extrapyramidal side-effects than olanzapine and increased prolactin levels compared to quetiapine.

Conclusions:

• Ziprasidone may be less efficacious than amisulpride, olanzapine, and risperidone, with its primary benefit being reduced weight gain.
• The high rate of participants discontinuing studies early impacts the overall validity of the findings.
• Further research is needed to fully elucidate the comparative effectiveness and safety profile of ziprasidone.